126 related articles for article (PubMed ID: 35435392)
1. p63-positive prostate carcinoma-A very rare presentation.
Lokesha SB; Chowdary BV; Kini JR
Indian J Pathol Microbiol; 2022; 65(2):448-451. PubMed ID: 35435392
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
3. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b.
Harvey AM; Grice B; Hamilton C; Truong LD; Ro JY; Ayala AG; Zhai QJ
Arch Pathol Lab Med; 2010 Jul; 134(7):983-8. PubMed ID: 20586625
[TBL] [Abstract][Full Text] [Related]
5. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of routine application of P504S, 34betaE12 and p63 immunostaining on 250 prostate needle biopsy specimens.
Pavlakis K; Stravodimos K; Kapetanakis T; Gregorakis A; Athanassiadou S; Tzaida O; Constantinides C
Int Urol Nephrol; 2010 Jun; 42(2):325-30. PubMed ID: 19655267
[TBL] [Abstract][Full Text] [Related]
8. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
9. ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity.
Uchida K; Ross H; Lotan T; Pignon JC; Signoretti S; Epstein JI; Illei PB
Hum Pathol; 2015 Mar; 46(3):384-9. PubMed ID: 25548110
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies.
Wu HH; Lapkus O; Corbin M
Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):285-9. PubMed ID: 15536326
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
12. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
Jiang Z; Wu CL; Woda BA; Dresser K; Xu J; Fanger GR; Yang XJ
Am J Surg Pathol; 2002 Sep; 26(9):1169-74. PubMed ID: 12218573
[TBL] [Abstract][Full Text] [Related]
13. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
Chastain EC; Oliva IV; Osunkoya AO
Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
[TBL] [Abstract][Full Text] [Related]
14. Performance comparison of anti-p504s (SP116) Rabbit Monoclonal Primary Antibody vs. Monoclonal Rabbit Anti-Human AMACR clone 13H4 when duplexed with VENTANA Basal Cell Cocktail (34βE12+p63) as a diagnostic aid for prostatic adenocarcinoma using immunohistochemistry.
Lindner V; Waydelich A; Chen CC; Jones C; Stratton SP
Virchows Arch; 2021 Aug; 479(2):337-343. PubMed ID: 33811532
[TBL] [Abstract][Full Text] [Related]
15. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
16. Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma.
Boran C; Kandirali E; Yilmaz F; Serin E; Akyol M
Urol Oncol; 2011; 29(6):614-23. PubMed ID: 20189848
[TBL] [Abstract][Full Text] [Related]
17. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody.
Oliai BR; Kahane H; Epstein JI
Am J Surg Pathol; 2002 Sep; 26(9):1151-60. PubMed ID: 12218571
[TBL] [Abstract][Full Text] [Related]
18. [Value of the antibody cocktail anti p63 + anti p504s for the diagnosis of prostatic cancer].
Molinié V; Hervé JM; Lebret T; Lugagne-Delpon PM; Saporta F; Yonneau L; Botto H; Baglin AC
Ann Pathol; 2004 Feb; 24(1):6-16. PubMed ID: 15192532
[TBL] [Abstract][Full Text] [Related]
19. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
Parsons JK; Gage WR; Nelson WG; De Marzo AM
Urology; 2001 Oct; 58(4):619-24. PubMed ID: 11597556
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
